OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Recent advances and perspectives on the development of circular RNA cancer vaccines	283
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	214
Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection	204
A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection	183
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging	162
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines	154
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials	127
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	123
Author Correction: SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate	103
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	101
A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system	91
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice	90
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI	89
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model	89
T cell independent antibody responses with class switch and memory using peptides anchored on liposomes	84
Understanding the rationales and information environments for early, late, and nonadopters of the COVID-19 vaccine	77
Author Correction: A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine	73
Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity	72
Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents	72
Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses	66
Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine	58
Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus	56
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine	55
Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation	54
Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis	54

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs	54
Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus	53
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2	52
Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk	52
Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity	51
Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models	51
Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis	50
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern	50
Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge	50
Immunological correlates of protection following vaccination with glucan particles containing Cryptococcus neoformans chitin deacetylases	48
Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine	47
Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice	47
Author Correction: “World in motion” – emulsion adjuvants rising to meet the pandemic challenges	45
Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort	44
Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic	44
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge	42